Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy

Pediatrics

Volumn 114, Issue 5, 2004, Pages

  Ghaffari, Guity ^a   Passalacqua, Dominick J ^a   Caicedo, Jennifer L ^a   Goodenow, Maureen M ^a,b   Sleasman, John W ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Children; Growth; HIV; Immune reconstitution; Immunization; Protease inhibitors

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; TETANUS TOXOID; VIRUS RNA;

ADOLESCENT; ADULT; ANTIGEN SPECIFICITY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MALE; PEDIATRICS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; T LYMPHOCYTE; TETANUS; TETANUS PROPHYLAXIS; TREATMENT OUTCOME; VIRUS REPLICATION; AIDS RELATED COMPLEX; BLOOD; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; PRESCHOOL CHILD; VIROLOGY; VIRUS LOAD;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNOCOMPETENCE; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 16644372369     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-0274     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recomendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mortal Wkly Rep. 2002;51:1-55
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497-1503
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860
4. Mellors JW, Munoz A, Giorgi J, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954
5. Palumbo P, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761
6. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Recomm Rep. 1998;47:1-44
7. Perez EE, Rose SL, Peyser B, et al. Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. J Infect Dis. 2001;183:579-588
8. Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953
9. Essajee SM, Kim M, Gonzalez C, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 1999;13:2523-2532
10. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863-868
11. Sleasman JW, Nelson RP, Goodenow MM, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr. 1999;134:597-606
12. Jankelevich S, Mueller BU, Mackall CL, et al. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis. 2001;183:1116-1120
13. Peruzzi M, Azzari C, Galli L, et al. Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin Exp Immunol. 2002;128:365-371
14. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43:1-12
15. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28:1109-1118
16. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:991-1001
17. Mueller BU, Nelson RP, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with HIV infection. Pediatrics. 1998;101:335-343
18. Mueller BU, Sleasman J, Nelson RP, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics. 1998;102:101-109
19. Williams A, Friedland F. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9:51-54
20. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528
21. Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107(5). Available at: www.pediatrics.org/ cgi/content/full/107/5/e77
22. Verweel G, van Rossum AM, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109(2). Available at: www.pediatrics.org/cgi/content/full/109/2/e25
23. Ghaffari G, Passalacqua DJ, Bender BS, et al. Human lymphocyte proliferation responses following primary immunization with rabies vaccine as neoantigen. Clin Diagn Lab Immunol. 2001;8:880-883
24. Sleasman JW, Leon BH, Aleixo LF, et al. Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation. Clin Diagn Lab Immunol. 1997;4:653-658
25. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitorcontaining combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics. 2001;108(4). Available at: www.pediatrics.org/cgi/content/full/108/4/e72
26. Nachman SA, Lindsey JC, Pelton S, et al. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr. Adolesc Med. 2002;156:497-503
27. Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201-207
28. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000;14:11-21
29. Valdez H. Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev. 2002;4:157-164
30. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533-540
31. Douek DC, Koup RA, McFarland RD. Effect of HIV on thymic function before and after antiretroviral therapy in children. J Infect Dis. 2000;181:1479-1482
32. Kou ZC, Puhr JS, Wu SS, et al. Combination antiretroviral therapy results in a rapid increase in t cell receptor variable region beta repertoire diversity within CD45RA CD8 T cells in human immunodeficiency virus-infected children. J Infect Dis. 2003;187:385-397
33. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116
34. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181:358-363
35. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109(4). Available at: www.pediatrics.org/cgi/content/full/109/4/e61
36. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003;17:361-370
37. Lecossier D, Bouchonnet F, Schneider P, et al. Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis. 2001;183:1009-1016
38. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001;7:712-718
39. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571
40. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766
41. Deeks SG, Hoh R, Grant RM, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002;185:315-323